Mock-up Updates Study Tags (field_study_tags) - Any - ADEQUATE Blog Call-outs CLIN-Net CoMeCT COVID-19 Data Ecraid ECRAID-Base EPI-Net EPOXI Mpox NeoDeco Partners People PIPELINE POS-ARI-ER POS-ARI-PC POS-cUTI POS-Disease X POS-VAP Primary Care PRUDENCE RECLAIM RECOVERY REMAP-CAP SNAP SOS Covid Training 22.01.2024 CoMeCT: Advancing trial and cohort study harmonisation Ecraid joins CoMeCT to promote a coordinated and collaborative approach to infectious disease clinical research. 17.01.2024 Webinar introduces manual with good practices for UTI laboratory management A useful new tool for tackling one of the most common bacterial infections. 16.01.2024 Sample Collection and Management Manual for Urinary Tract Infections Good practices in routine UTI laboratory management. 12.12.2023 Participants reflect on recent ESCMID course in Prague 30.11.2023 Blog post: Nebulized amikacin – preventing positive cultures or VAP? A paper on ventilator-associated pneumonia reminds Marc Bonten about his PhD and problems still unsolved 30 years later. 29.11.2023 Ecraid and Sanofi join forces to tackle impact of respiratory viruses Data from older patients consulting their GP with respiratory infection symptoms will inform Sanofi’s vaccine development. Load More
22.01.2024 CoMeCT: Advancing trial and cohort study harmonisation Ecraid joins CoMeCT to promote a coordinated and collaborative approach to infectious disease clinical research.
17.01.2024 Webinar introduces manual with good practices for UTI laboratory management A useful new tool for tackling one of the most common bacterial infections.
16.01.2024 Sample Collection and Management Manual for Urinary Tract Infections Good practices in routine UTI laboratory management.
30.11.2023 Blog post: Nebulized amikacin – preventing positive cultures or VAP? A paper on ventilator-associated pneumonia reminds Marc Bonten about his PhD and problems still unsolved 30 years later.
29.11.2023 Ecraid and Sanofi join forces to tackle impact of respiratory viruses Data from older patients consulting their GP with respiratory infection symptoms will inform Sanofi’s vaccine development.
